MUSC Internal Medicine

Congrats to @kurt_prins on his induction into the @the_asci! He is the first MUSC physician-scientist to receive this distinction since 2014.

Congrats to Dr. Macharla on being named one of the @MUSC_COM residents of the month!

It was a fantastic day showcasing the depth and diversity of research across the @MUSC_COM Department of Medicine. Proud to highlight the incredible work of our faculty, residents, fellows, research staff, and students who make it all possible.#AcademicMedicine #MedicalResearch

We’re excited to announce our 2027–2028 Internal Medicine Chief Residents! Congratulations to Drs. Hayley Fowler, Mark Mandak, Megan Minchak, and Michael Vinzani!👏 Learn more about our chiefs: bit.ly/42b175o #MUSCIMResidency #MUSC #IMChiefResidents

Congratulations to @MUSChealth cardiologist & physician-scientist @kurt_prins on his election to the prestigious American Society for Clinical Investigation. He is the 1st MUSC physician-scientist elected since 2014. Learn more: bit.ly/48e9dxw

@MUSC_Cardiology bringing the 🔥 at #ACC26! From the podium to packed poster sessions — incredible representation by our faculty and a huge showing from our trainees. Proud to see the next generation shining (and maybe outshining us just a bit 😉). Great science, even better people. @PamelaBMorris @kurt_prins

The results of the CADENCE trial are now published in @CircAHA with simultaneous presentation @ACCinTouch by @mardigomberg. CADENCE represents an important step forward for patients with combined post- and pre-capillary pulmonary hypertension (CpcPH) in the setting of HFpEF—an area with substantial unmet need. In this phase 2 study, treatment with sotatercept led to meaningful reductions in pulmonary vascular resistance (PVR), which translated into improved RV–PA coupling and reductions in natriuretic peptide levels. Importantly, these hemodynamic improvements were accompanied by favorable signals across multiple clinical domains for 0.3mg/kg dose: • Improvement in 6-minute walk distance • Improvements in New York Heart Association functional class (exploratory endpoint) • Prolonged time to clinical worsening (exploratory endpoint) In addition, there were reductions in left heart filling pressures, along with decreases in left atrial volume index—suggesting potential effects on cardiac remodeling and congestion. Strong safety profile with no excess bleeding compared to placebo (75% on systemic anticoagulation). Together, these findings reinforce the biologic rationale for targeting the pulmonary vasculature in CpcPH-HFpEF with sotatercept and provide strong momentum as we move toward phase 3. Grateful to the patients, investigators, and collaborators who made this work possible—and excited for what comes next. @jeanlucvachiery @MUSC_Cardiology ahajournals.org/doi/10.1161/CI…

Could our genes help unlock safer treatments for childhood lupus? Dr. Betty Tsao at MUSC is studying rare genetic mutations to uncover new pathways that could lead to more targeted and less toxic therapies. Read more: tinyurl.com/8w8pakf3 #ChangingWhatsPossible

Dr. Abi Siva is leading a new clinical trial to help women facing both triple negative breast cancer and heart disease. These patients often have no clear treatment options. She is working to change that. Learn More: web.musc.edu/about/news-cen…

Exciting news! MUSC’s Digestive Disease Research Core Center, led by Dr. Don Rockey, has earned a 5-year renewal of its prestigious NIH grant. As one of only 17 centers in the United States, we take pride in being a national leader in the field.

From trials to technologies, MUSC research is translating science into solutions. This month, we recognize the teams driving innovation in care and discovery. Learn more: tinyurl.com/53fy3wvc #MedicalResearchMonth #ChangingWhatsPossible

FSR is proud to lead the initiative that FMLA now protects patients in clinical trials, a game-changer for sarcoidosis & ALL rare diseases. Grateful to Dr. Ennis James, @MUSChealth for sharing why this matters. Read more: statnews.com/2025/09/24/cli… #Sarcoidosis #FMLA

Meaningful relationships and groundbreaking research go hand in hand for Dr. DeAnna Baker Frost. At MUSC, she specializes in rheumatology with a focus on scleroderma, inspired by the strength of those she serves. #WiMMonth #ChangingWhatsPossible

Between 30–50% of lupus patients develop lupus nephritis, and half progress to kidney failure. MUSC researcher Jim Oates, MD, is developing a new approach to prevention. bit.ly/4mYeyye

Milestone moment: MUSC Health has performed its 750th Watchman procedure for patients with AFib, offering an alternative to long-term blood thinners & lowering stroke risk. Proud of our cath lab & structural heart teams for #ChangingWhatsPossible in heart care. #AFib

Save the date! The 1st Annual Sarcoidosis Patient Summit is Sat. Sept. 6 at MUSC Health. —Expert panels — Q&A sessions — Supportive resources —In person or virtual —11 a.m. – 2 p.m. Learn more: facebook.com/events/3163764…

Congratulations to Dr. Van Beusecum on receiving the 2024 Lupus Innovation Award from the @LupusResearch Alliance! 👏 Read more: lupusresearch.org/lupus-research…

We're excited to announce the Internal Medicine Chief Residents for 2026–2027! Congratulations to Drs. Sara Armstrong, Vincent Bolus, Maria Roell, and Hannah Story! Read more: medicine.musc.edu/departments/do… #MUSCIMResidency #MUSC #IMChiefResidents

Today, we celebrate the dedicated residents and fellows who keep our hospital running, provide compassionate patient care, and mentor the next generation of physicians. 🎉 Thank you to our incredible residents and fellows! 💙 #ThankAResidentDay #MUSCIM #GratefulForResidents

@MUSC_IM resident Dr. Khairutdinov presented not one but two complex cases at #TCT2024 under the mentorship of Dr. Fernandes. Congratulations Ilgizar!